Page 64 - Amgen News Today

Stocks in Toronto gained strength by the end of the Thursday session, following up on the good vibes given off by Bank of Canada Tiff Macklem that interest rates are not likely to jump any time soon. The TSX Composite recovered 94.67 points to ...

Stock surged late Thursday on its first-quarter profit beat as investors zero in on its potential rivals to Eli Lilly's (LLY) and Novo Nordisk's (NVO) obesity…

Amgen reported a slightly lower first-quarter profit on Thursday, citing higher operating and interest expense from its recent acquisition of rare disease drugmaker Horizon Therapeutics, partially...

Beacon Harbor Wealth Advisors Inc. cut its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 6.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,993 shares of the medical research company’s stock after selling 910 shares […]

Amgen is among several drugmakers racing to join the red-hot weight loss drug space dominated by Novo Nordisk and Eli Lilly.

(Bloomberg) -- Amgen Inc.’s shares soared after its chief executive officer said he was “very encouraged” by early results from a study of the company’s experimental obesity drug, MariTide. Most Read from BloombergSaudi Arabia Steps Up Arrests Of Those Attacking Israel OnlineApple Rallies Most in 18 Months on Upbeat Forecast, BuybackEverything Apple Plans to Show at May 7 ‘Let Loose’ iPad EventTrump Auditions VP Picks Before Wealthy Donors in Palm BeachT...

Amgen is among several drugmakers racing to join the red-hot weight loss drug space dominated by Novo Nordisk and Eli Lilly.

By Deena Beasley (Reuters) -Amgen on Thursday said it was very encouraged after completing an interim analysis of its mid-stage study of experimental ...

Horizon Therapeutics, which Amgen bought last year for around $28 billion, contributed $914 million in sales.

By Deena Beasley (Reuters) - Amgen reported a slightly lower first-quarter profit on Thursday, citing higher operating and interest expense from its recent acquisition of rare disease drugmaker Horizon Therapeutics, partially offset by double-digit...